HIV and co-infections

Immunological Reviews

Volumn 254, Issue 1, 2013, Pages 114-142

  Chang, Christina C ^a,b   Crane, Megan ^a,b   Zhou, Jingling ^b   Mina, Michael ^c   Post, Jeffrey J ^d,e   Cameron, Barbara A ^c   Lloyd, Andrew R ^c,e   Jaworowski, Anthony ^a,b   French, Martyn A ^f,g   Lewin, Sharon R ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Cryptococcosis; Hepatitis B; Hepatitis C; HIV; Immune restoration disease; Immunology; Malaria; Tuberculosis

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIRETROVIRUS AGENT; BCG VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C VACCINE; LIPOPOLYSACCHARIDE; LIVE VACCINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACUTE DISEASE; ANTIVIRAL THERAPY; ARTICLE; B LYMPHOCYTE; BCG VACCINATION; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOKINE RESPONSE; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INNATE IMMUNITY; LIVER DISEASE; LIVER FIBROSIS; LUNG TUBERCULOSIS; MACROPHAGE; MALARIA; MEDICAL HISTORY; MONOCYTE; MORBIDITY; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; PATHOGEN LOAD; PATHOGENESIS; PLASMODIUM FALCIPARUM; PREDICTIVE VALUE; PREGNANCY; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE; TH1 CELL; TUBERCULOSIS;

AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; CRYPTOCOCCOSIS; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; MALARIA; TUBERCULOSIS;

EID: 84879321760     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12063     Document Type: Article

References (346)

1. Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380:2095-2128.
2. World Health Organization. Global Tuberculosis Report 2012. ISBN 978 92 4 156450 2, 2013. Available from http://www.who.int/tb/publications/global_report/en/.
3. Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol 2010;185:15-22.
4. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. Tuberculosis and HIV co-infection. PLoS Pathog 2012;8:e1002464.
5. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687-1693.
6. Crampin AC, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010;24:417-426.
7. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006;4:469-476.
8. Diedrich CR, Flynn JL. HIV-1/Mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun 2011;79:1407-1417.
9. Geldmacher C, Koup RA. Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection. Trends Immunol 2012;33:207-214.
10. Diedrich CR, et al. Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS ONE 2010;5:e9611.
11. Geldmacher C, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008;198:1590-1598.
12. Geldmacher C, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med 2010;207:2869-2881.
13. Sutherland JS, et al. Polyfunctional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment. J Immunol 2010;184:6537-6544.
14. Sarrazin H, et al. Association between tuberculin skin test reactivity, the memory CD4 cell subset, and circulating FoxP3-expressing cells in HIV-infected persons. J Infect Dis 2009;199:702-710.
15. Patel NR, et al. HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol 2007;179:6973-6980.
16. Patel NR, Swan K, Li X, Tachado SD, Koziel H, Impaired M. tuberculosis-mediated apoptosis in alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3. J Leukoc Biol 2009;86:53-60.
17. Smith MB, Boyars MC, Veasey S, Woods GL. Generalized tuberculosis in the acquired immune deficiency syndrome. Arch Pathol Lab Med 2000;124:1267-1274.
18. Wilkinson KA, et al. Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med 2009;180:674-683.
19. Suthar AB, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012;9:e1001270.
20. HIV Causal collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis 2012;54:1364-1372.
21. Meintjes G, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008;8:516-523.
22. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009;48:829-831.
23. Elliott JH, et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 2009;200:1736-1745.
24. Oliver BG, et al. Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. J Infect Dis 2010;202:1728-1737.
25. Oliver BG, Elliott JH, Price P, Phillips M, Cooper DA, French MA. Tuberculosis after commencing antiretroviral therapy for HIV infection is associated with elevated CXCL9 and CXCL10 responses to Mycobacterium tuberculosis antigens. J Acquir Immune Defic Syndr 2012;61:287-292.
26. Naidoo K, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012;157:313-324.
27. Blanc FX, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-1481.
28. Havlir DV, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365:1482-1491.
29. Price P, Murdoch DM, Agarwal U, Lewin SR, Elliott JH, French MA. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev 2009;22:651-663.
30. Meintjes G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009;48:667-676.
31. Marais S, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 2013;56:450-460.
32. Conesa-Botella A, et al. Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome. J Acquir Immune Defic Syndr 2011;58:463-468.
33. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000;1:107-115.
34. Simonney N, et al. Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patients. Tuberculosis 2008;88:453-461.
35. Bourgarit A, et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. J Immunol 2009;183:3915-3923.
36. Bourgarit A, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006;20:F1-F7.
37. Tan DB, Yong YK, Tan HY, et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med 2008;9:307-316.
38. Mahnke YD, et al. Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 2012;119:3105-3112.
39. Barber DL, et al. Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 2010;116:3485-3493.
40. Tieu HV, et al. Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. AIDS Res Hum Retroviruses 2009;25:1083-1089.
41. Meintjes G, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008;178:1083-1089.
42. Seddiki N, et al. Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur J Immunol 2009;39:391-403.
43. Haddow LJ, Dibben O, Moosa MY, Borrow P, Easterbrook PJ. Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2011;25:1163-1174.
44. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313-326.
45. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011;89:207-215.
46. Pean P, et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood 2012;119:3315-3320.
47. Tadokera R, et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J 2011;37:1248-1259.
48. Stone SF, Price P, Keane NM, Murray RJ, French MA. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 2002;3:21-27.
49. Meintjes G, et al. Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2012;186:369-377.
50. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol 2012;10:150-156.
51. von Reyn CF, Bakari M, Arbeit RD, Lahey T, Ramadhani A, Egwaga S. New vaccines for the prevention of tuberculosis in human immunodeficiency virus infection. Int J Tuberc Lung Dis 2012;16:718-723.
52. World Health Organization. Revised BCG Vaccination Guidelines for Infants at Risk for HIV Infection. Weekly Epidemiological Record 2007 May 25. Available from http://www.who.int/immunization/wer8221bcg_May07_position_paper.pdf.
53. von Reyn CF, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010;24:675-685.
54. Abdool KS, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365:1492-1501.
55. Kwon-Chung KJ, Boekhout T, Wickes BL, Fell JW. Systematics of the Genus Cryptococcus and its type species C. neoformans. In: Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A eds. Cryptococcus - From Human Pathogen to Model Yeast. Washington, DC: ASM Press, 2011:3-15.
56. Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006;20:507-544 vi.
57. Mwaba P, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001;77:769-773.
58. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009;23:525-530.
59. Casadevall A, Pirofski LA. Feasibility and prospects for a vaccine to prevent cryptococcosis. Med Mycol 2005;43:667-680.
60. Casadevall A, Dadachova E, Pirofski L. Vaccines and antibody therapies from Cryptococcus neoformans to melanoma. In: Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A eds. Cryptococcus - From Human Pathogen to Model Yeast. Washington, DC: ASM Press, 2011:537-546.
61. Hole CR, Wormley FL Jr. Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol 2012;3:291. Available from: PM:22973262
62. Hoag KA, Lipscomb MF, Izzo AA, Street NE. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol 1997;17:733-739.
63. Hoag KA, Street NE, Huffnagle GB, Lipscomb MF. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol 1995;13:487-495.
64. Siddiqui AA, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol 2005;174:1746-1750.
65. Jarvis JN, et al. The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal menegitis. J Infect Dis 2013;doi: 10.1093/infdis/jit099.
66. Huffnagle GB, et al. Cutting edge: role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol 1999;163:4642-4646.
67. Johnston SA, May RC. Cryptococcus interactions with macrophages: evasion and manipulation of the phagosome by a fungal pathogen. Cell Microbiol 2013;15:403-411.
68. Sabiiti W, May RC. Mechanisms of infection by the human fungal pathogen Cryptococcus neoformans. Future Microbiol 2012;7:1297-1313.
69. Idnurm A, Bahn YS, Nielsen K, Lin X, Fraser JA, Heitman J. Deciphering the model pathogenic fungus Cryptococcus neoformans. Nat Rev Microbiol 2005;3:753-764.
70. Rodrigues ML, Casadevall A, Zaragoza O. The architecture and antigenic composition of the polysaccharide capsule. In: Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A eds. Cryptococcus: From Human Pathogen to Model Yeast. Washington, DC: ASM Press, 2011:43-54.
71. Wiesner DL, et al. Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. MBio 2012;3:e00196-12.
72. Clerici M, Shearer GM. A TH1->TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
73. Ieong MH, Reardon CC, Levitz SM, Kornfeld H. Human immunodeficiency virus type 1 infection of alveolar macrophages impairs their innate fungicidal activity. Am J Respir Crit Care Med 2000;162:966-970.
74. Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 2011;1399:96-115.
75. Sorce S, Myburgh R, Krause KH. The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 2011;93:297-311.
76. Ivey NS, MacLean AG, Lackner AA. Acquired immunodeficiency syndrome and the blood-brain barrier. J Neurovirol 2009;15:111-122.
77. Goldberg SH, et al. CXCR3 expression in human central nervous system diseases. Neuropathol Appl Neurobiol 2001;27:127-138.
78. Haddow LJ, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010;10:791-802.
79. Zolopa A, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 2009;4:e5575.
80. Sax PE. Cryptococcal Meningitis Study Stopped - Early HIV Therapy Clearly Harmful. http://blogsjwatchorg/hiv-id-observations/indexphp/cryptococcal-meningitis-study-stopped-early-hiv-therapy-clearly-harmful/2012/06/02/2012June 2.Available from http://blogs.jwatch.org/hiv-id-observations/index.php/cryptococcal-meningitis-study-stopped-early-hiv-therapy-clearly-harmful/2012/06/02/.
81. Makadzange AT, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010;50:1532-1538.
82. Bisson GP, et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis 2013; doi: 10.1093/cid/cit019.
83. Boulware DR, et al. ART initiation within the first 2 weeks of cryptococcal meningitis is associated with higher mortality: A multisite randomized trial. In: Conference on Retroviruses and Opportunistic Infections; 2013. Atlanta, Georgia.
84. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005;19:1043-1049.
85. Boulware DR, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010;202:962-970.
86. Chang CC, et al. Clinical and mycological predictors of Cryptococcosis-associated Immune reconstitution inflammatory syndrome (C-IRIS). AIDS 2013; in press.
87. Bicanic T, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009;51:130-134.
88. Chang CC, et al. Cryptococcosis-IRIS is associated with lower Cryptococcus-specific IFN-gamma responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis 2013; in press.
89. Zaunders JJ, et al. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol 2009;183:2827-2836.
90. Lortholary O, Improvisi L, Rayhane N, et al. Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection. Infect Immun 1999;67:6314-6320.
91. Jarvis JN, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011;53:1019-1023.
92. Hansen J, et al. Large Scale Evaluation of the Immuno-Mycologics Inc. (IMMY) Lateral Flow and Enzyme-linked Immunoassays for the detection of Cryptococcal Antigen in Serum and Cerebrospinal Fluid. Clin Vaccine Immunol 2013;20:52-55.
93. Datta K, Pirofski LA. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res 2006;6:525-536.
94. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994;38:460-464.
95. Kleinschek MA, et al. Administration of IL-23 engages innate and adaptive immune mechanisms during fungal infection. Int Immunol 2010;22:81-90.
96. Jarvis JN, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012;26:1105-1113.
97. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004;189:2185-2191.
98. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007;7:402-409.
99. Rosenthal E, et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007;14:183-188.
100. Rosenthal E, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med 2009;10:282-289.
101. Smith C, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537-1548.
102. Hoffmann CJ, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009;23:1881-1889.
103. Nikolopoulos GK, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009;48:1763-1771.
104. Thio CL, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926.
105. Weber R, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013;14:195-207.
106. Weber R, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-1641.
107. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007;85:16-23.
108. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-352.
109. Benhamou Y, Hepatitis B. in the HIV-coinfected patient. J Acquir Immune Defic Syndr 2007;45(Suppl):S57-S65.
110. Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007;45:624-632.
111. Thio CL, Locarnini S. Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev 2007;9:40-53.
112. Maini MK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-1280.
113. Sprengers D, et al. Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans. J Hepatol 2006;45:182-189.
114. Evans A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008;48:759-769.
115. Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005;41:771-778.
116. Zhang HH, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat 2010;17(Suppl):34-43.
117. Das A, et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 2012;189:3925-3935.
118. Bayard F, Godon O, Nalpas B, et al. T-cell responses to hepatitis B splice-generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP-FIBRO. J Viral Hepat 2012;19:872-880.
119. Zhou Y, et al. Hepatitis B virus protein X-induced expression of the CXC chemokine IP-10 is mediated through activation of NF-kappaB and increases migration of leukocytes. J Biol Chem 2010;285:12159-12168.
120. Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003;74:360-369.
121. Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 2004;39:1220-1229.
122. Sahin H, et al. Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes. Hepatology 2013;57:797-805.
123. Beckebaum S, Cicinnati VR, Dworacki G, et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 2002;104:138-150.
124. Beckebaum S, et al. Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology 2003;109:487-495.
125. Zheng BJ, et al. Selective functional deficit in dendritic cell-T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepat 2004;11:217-224.
126. van der Molen RG, et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004;40:738-746.
127. Xie Q, et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect 2009;11:515-523.
128. Xu N, Yao HP, Sun Z, Chen Z. Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma. Acta Pharmacol Sin 2008;29:239-244.
129. Visvanathan K, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45:102-110.
130. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011;55:762-769.
131. Chen Z, et al. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008;128:400-408.
132. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79:7269-7272.
133. Ma R, Du JL, Huang J, Wu CY. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem Biophys Res Commun 2007;361:537-542.
134. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005;23:5263-5270.
135. Rong Y, et al. Association of Toll-like Receptor 3 Polymorphisms with Chronic Hepatitis B and Hepatitis B-Related Acute-on-Chronic Liver Failure. Inflammation 2013;36:413-418.
136. Sprengers D, et al. Different composition of intrahepatic lymphocytes in the immune-tolerance and immune-clearance phase of chronic hepatitis B. J Med Virol 2006;78:561-568.
137. Li F, et al. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. Gastroenterology 2013;144:392-401.
138. Ratnam DT, Sievert W, Visvanathan K. Natural killer cells display impaired responses to toll like receptor 9 that support viral persistence in chronic hepatitis B. Cell Immunol 2012;279:109-115.
139. Dunn C, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007;204:667-680.
140. Liu FW, et al. Expression of TRAIL in liver tissue from patients with different outcomes of HBV infection. Clin Res Hepatol Gastroenterol 2012; pii: S2210-7401(12)00256-2. doi: 10.1016/j.clinre.2012.09.009.
141. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160:577-582.
142. Colin JF, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-1310.
143. Gilson RJ, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997;11:597-606.
144. Audsley J, et al. HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection. J Med Virol 2012;84:993-1001.
145. Thio CL, et al. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS 2013;27:191-201.
146. Chang JJ, et al. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol 2005;79:3038-3051.
147. Chang JJ, et al. Impaired quality of the HBV-specific T-cell response in HIV-1-HBV co-infection. J Virol 2009;83:7649-7658.
148. Crane M, et al. No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J Virol 2010;84:2657-2665.
149. Chang JJ, et al. The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology 2007;46:1332-1340.
150. Iser DM, Avihingsanon A, Wisedopas N, et al. Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS 2011;25:197-205.
151. Jiang W, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009;199:1177-1185.
152. Rajasuriar R, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation. J Infect Dis 2010;202:1254-1264.
153. Brenchley JM, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
154. Marchetti G, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 2011;25:1385-1394.
155. Sandler NG, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011;141:1220-1230.
156. Mathurin P, Deng QG, Keshavarzian A, Choudhary S, Holmes EW, Tsukamoto H. Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology 2000;32:1008-1017.
157. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003;37:1043-1055.
158. Dolganiuc A, et al. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007;133:1627-1636.
159. Balagopal A, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008;135:226-233.
160. Garcia-Alvarez M, et al. Bacterial DNA translocation and liver disease severity among HIV-infected patients with chronic hepatitis C. J Acquir Immune Defic Syndr 2012;61:552-556.
161. Masgala A, Bonovas S, Nikolopoulos GK. Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection. Mini Rev Med Chem 2012;12:890-904.
162. Marcellin P, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475.
163. Martin-Carbonero L, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011;25:73-79.
164. Boni C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215-4225.
165. Kondo Y, et al. Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity. J Med Virol 2004;74:425-453.
166. Lau GK, et al. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther 2007;12:705-718.
167. Fisicaro P, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010;138:682-693.
168. Sherman A, et al. Augmentation of HBV specific cellular immunity with PD-1/PD-L1 Blockade in HBV and HIV/HBV coinfected patients treated with Adefovir. AIDS Res Hum Retroviruses 2013; doi: 10.1089/aid.2012.0320.
169. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
170. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
171. Kosi L, et al. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. J Viral Hepat 2012;19:801-810.
172. de Vries-Sluijs TE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010;139:1934-1941.
173. Piroth L, et al. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 2010;53:1006-1012.
174. Psevdos G Jr., Kim JH, Suh JS, Sharp VL. Predictors of loss of hepatitis B surface antigen in HIV-infected patients. World J Gastroenterol 2010;16:1093-1096.
175. Fried MW, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-434.
176. Liaw YF, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
177. Arendt E, et al. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients. Viral Immunol 2012;25:442-447.
178. Jaroszewicz J, et al. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. PLoS ONE 2012;7:e43143.
179. Tan AT, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010;52:330-339.
180. Jaroszewicz J, et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011;16:915-924.
181. He D, Yan G, Wang Y. Serum levels of interleukin-12 in various clinical states with hepatitis B virus infection. Cell Immunol 2012;272:162-165.
182. Ma SW, et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol 2012;56:775-781.
183. Wu JF, et al. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology 2010;138:165-172.
184. Park Y, Park JY, Han KH, Kim HS. Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy. Hepatobiliary Pancreat Dis Int 2012;11:499-506.
185. Andrade BB, et al. Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons co-infected with HIV and hepatitis viruses. J Infect Dis 2013; doi: 10.1093/infdis/jit03.
186. Matthews GV, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008;48:1062-1069.
187. Avihingsanon A, et al. Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand. AIDS Res Ther 2012;9:6.
188. Rey D, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000;18:1161-1165.
189. Landrum ML, et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009;27:4731-4738.
190. Landrum ML, et al. The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. Am J Epidemiol 2011;173:84-93.
191. Shepard CW Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567.
192. McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007;45(Suppl):S47-S56.
193. European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012;32(Suppl):2-8.
194. Terrault NA, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012;18:716-726.
195. Bica I, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
196. Davis GL. Hepatitis C virus genotypes and quasispecies. Am J Med 1999;107:21S-26S.
197. Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS. Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol 2010;84:6096-6102.
198. McHutchison JG, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-593.
199. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011;8:257-264.
200. Sulkowski MS. HCV therapy in HIV-infected patients. Liver Int 2013;33(Suppl):63-67.
201. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001;75:7059-7066.
202. Nanda S, et al. Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS ONE 2008;3:e3442.
203. Su AI, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002;99:15669-15674.
204. Golden-Mason L, Castelblanco N, O'Farrelly C, Rosen HR. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol 2007;81:9292-9298.
205. Amadei B, et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 2010;138:1536-1545.
206. Post J, Ratnarajah S, Lloyd AR. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009;66:733-756.
207. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998;29:207-213.
208. Vejbaesya S, Songsivilai S, Tanwandee T, Rachaibun S, Chantangpol R, Dharakul T. HLA association with hepatitis C virus infection. Hum Immunol 2000;61:348-353.
209. Chang KM, et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 2001;33:267-276.
210. Diepolder HM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-1007.
211. Ferrari C, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994;19:286-295.
212. Lechner F, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
213. Grakoui A, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-662.
214. Gruner NH, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000;181:1528-1536.
215. Sobao Y, Tomiyama H, Nakamura S, Sekihara H, Tanaka K, Takiguchi M. Visual demonstration of hepatitis C virus-specific memory CD8(+) T-cell expansion in patients with acute hepatitis C. Hepatology 2001;33:287-294.
216. Fafi-Kremer S, et al. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 2010;207:2019-2031.
217. Pestka JM, Zeisel MB, Blaser E, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007;104:6025-6030.
218. Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 2010;84:5067-5077.
219. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001;79:515-536.
220. Botarelli P, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993;104:580-587.
221. Abrignani S. Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view. Springer Semin Immunopathol 1997;19:47-55.
222. Freeman AJ, et al. The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. J Hepatol 2003;38:349-356.
223. Khakoo SI, et al. Lymphocyte and macrophage phenotypes in chronic hepatitis C infection. Correlation with disease activity. Am J Pathol 1997;150:963-970.
224. Fiore G, Angarano I, Caccetta L, et al. In-situ immunophenotyping study of hepatic-infiltrating cytotoxic cells in chronic active hepatitis C. Eur J Gastroenterol Hepatol 1997;9:491-496.
225. Nelson DR, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997;158:1473-1481.
226. Billerbeck E, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci USA 2010;107:3006-3011.
227. He XS, et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999;96:5692-5697.
228. Neumann-Haefelin C, et al. Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology 2008;47:1824-1836.
229. Cox AL, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005;201:1741-1752.
230. Radziewicz H, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007;81:2545-2553.
231. Accapezzato D, et al. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest 2004;113:963-972.
232. Rushbrook SM, et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 2005;79:7852-7859.
233. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992;15:567-571.
234. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
235. Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology 2009;49:676-688.
236. Helbig KJ, et al. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J Virol 2009;83:836-846.
237. Askarieh G, et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010;51:1523-1530.
238. Grebely J, et al. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology 2013; doi: 10.1002/hep.26263.
239. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425-456.
240. Kirn A, Bingen A, Steffan AM, Wild MT, Keller F, Cinqualbre J. Endocytic capacities of Kupffer cells isolated from the human adult liver. Hepatology 1982;2:216-222.
241. Seki E, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13:1324-1332.
242. Leandro G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-1642.
243. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-816.
244. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36(Suppl):S21-S29.
245. Danta M, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008;197:1558-1566.
246. Thomas DL, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.
247. Martinez-Sierra C, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003;36:491-498.
248. Piroth L, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998;12:381-388.
249. Kim AY, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med 2006;3:e492.
250. Kim AY, Chung RT. Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology 2009;137:795-814.
251. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994;84:1020-1023.
252. Thomas DL, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-695.
253. Daar ES, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001;26:466-472.
254. Lin W, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008;134:803-811.
255. Revie D, Salahuddin SZ. Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virol J 2011;8:346.
256. Netski DM, Mosbruger T, Astemborski J, Mehta SH, Thomas DL, Cox AL. CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. J Infect Dis 2007;195:857-863.
257. Barrett L, et al. Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfection. J Viral Hepat 2011;18:170-180.
258. Dutoit V, Ciuffreda D, Comte D, Gonvers JJ, Pantaleo G. Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur J Immunol 2005;35:3493-3504.
259. Kim AY, et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 2005;105:1170-1178.
260. Harcourt G, Gomperts E, Donfield S, Klenerman P. Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut 2006;55:1484-1487.
261. Alatrakchi N, Graham CS, He Q, Sherman KE, Koziel MJ. CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. J Infect Dis 2005;191:702-709.
262. Kuntzen T, et al. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS 2008;22:203-210.
263. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006;44:47-55.
264. Balagopal A, et al. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS 2009;23:2397-2404.
265. Tuyama AC, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010;52:612-622.
266. Guaraldi G, et al. Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. Arch Med Res 2011;42:690-697.
267. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998;12:2289-2293.
268. French MA. Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on. Med J Aust 2012;196:318-321.
269. Yunihastuti E, et al. Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART. Clin Immunol 2011;139:32-39.
270. Cameron BA, Emerson CR, Workman C, Kelly MD, Lloyd AR, Post JJ. Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy. J Clin Immunol 2011;31:1079-1083.
271. Kang F, et al. Transient Liver Injury Associated With the Early Recovery of HCV-Specific T-Cell Responses and HCV Rebound in HIV-1/HCV Coinfected Patients Undergoing Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr 2013;62:135-142.
272. Page-Shafer K, Hahn JA, Lum PJ. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS 2007;21:1967-1969.
273. Osburn WO, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010;138:315-324.
274. Leroux-Roels G, et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005;1:61-65.
275. Leroux-Roels G, et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004;22:3080-3086.
276. Frey SE, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010;28:6367-6373.
277. Stamataki Z, Coates S, Abrignani S, Houghton M, McKeating JA. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis 2011;204:811-813.
278. Barnes E, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4:115ra1.
279. Study of a New MVA Vaccine for Hepatitis C Virus. US National Institutes of Health, ClinicalTrials gov 2013. Available from http://clinicaltrials.gov/ct2/show/NCT01296451?term=HCV+vaccine&rank=14.
280. Staged Phase I/II Hepatitis C Prophylactic Vaccine. US National Institutes of Health, ClinicalTrials gov 2013. Available from http://clinicaltrials.gov/ct2/show/NCT01436357?term=NCT01436357&rank=1.
281. Keoshkerian E, et al. A novel assay for detection of hepatitis C virus-specific effector CD4(+) T cells via co-expression of CD25 and CD134. J Immunol Methods 2012;375:148-158.
282. Murray CJ, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012;379:413-431.
283. Phyo AP, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012;379:1960-1966.
284. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 1999;5:340-343.
285. Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961;192:733-737.
286. McGregor IA, Williams K, Goodwin LG. Pyrimethamine and Sulphadiazine in Treatment of Malaria. Br Med J 1963;2:728-729.
287. Sabchareon A, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991;45:297-308.
288. Riley EM, Wagner GE, Akanmori BD, Koram KA. Do maternally acquired antibodies protect infants from malaria infection? Parasite Immunol 2001;23:51-59.
289. Ricke CH, et al. Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A. J Immunol 2000;165:3309-3316.
290. Salanti A, Dahlback M, Turner L, et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 2004;200:1197-1203.
291. Kern P, Hemmer CJ, Van Damme J, Gruss HJ, Dietrich M. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 1989;87:139-143.
292. Jakobsen PH, et al. Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria. Infect Immun 1994;62:4374-4379.
293. Grau GE, Piguet PF, Vassalli P, Lambert PH. Involvement of tumour necrosis factor and other cytokines in immune-mediated vascular pathology. Int Arch Allergy Appl Immunol 1989;88:34-39.
294. Kwiatkowski D, et al. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990;336:1201-1204.
295. Lyke KE, Burges R, Cissoko Y, et al. Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 2004;72:5630-5637.
296. Day NP, et al. The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis 1999;180:1288-1297.
297. Prakash D, Fesel C, Jain R, Cazenave PA, Mishra GC, Pied S. Clusters of cytokines determine malaria severity in Plasmodium falciparum-infected patients from endemic areas of Central India. J Infect Dis 2006;194:198-207.
298. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE. Maternal antibodies block malaria. Nature 1998;395:851-852.
299. Moormann AM, et al. Malaria and pregnancy: placental cytokine expression and its relationship to intrauterine growth retardation. J Infect Dis 1999;180:1987-1993.
300. Suguitan AL Jr, et al. Changes in the levels of chemokines and cytokines in the placentas of women with Plasmodium falciparum malaria. J Infect Dis 2003;188:1074-1082.
301. Chandramohan D, Greenwood BM. Is there an interaction between human immunodeficiency virus and Plasmodium falciparum? Int J Epidemiol 1998;27:296-301.
302. Greenberg AE, et al. Plasmodium Falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study of 587 children. N Engl J Med 1991;325:105-109.
303. Allen S, et al. Human immunodeficiency virus and malaria in a representative sample of childbearing women in Kigali, Rwanda. J Infect Dis 1991;164:67-71.
304. Colebunders R, et al. Incidence of malaria and efficacy of oral quinine in patients recently infected with human immunodeficiency virus in Kinshasa, Zaire. J Infect 1990;21:167-173.
305. Simooya OO, Mwendapole RM, Siziya S, Fleming AF. Relation between falciparum malaria and HIV seropositivity in Ndola Zambia. BMJ 1988;297:30-31.
306. Whitworth JA, Hewitt KA. Effect of malaria on HIV-1 progression and transmission. Lancet 2005;365:196-197.
307. Laufer MK, et al. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis 2006;193:872-878.
308. Steketee RW, et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996;55(Suppl):42-49.
309. ter Kuile FO, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 2004;71(Suppl):41-54.
310. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg 1989;83:293-303.
311. O'Neil-Dunne I, et al. Gravidity-dependent production of antibodies that inhibit binding of Plasmodium falciparum-infected erythrocytes to placental chondroitin sulfate proteoglycan during pregnancy. Infect Immun 2001;69:7487-7492.
312. Staalsoe T, et al. Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia. J Infect Dis 2001;184:618-626.
313. Staalsoe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K, Hviid L. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 2004;363:283-289.
314. Duffy PE, Fried M. Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. Infect Immun 2003;71:6620-6623.
315. Jaworowski A, et al. Relationship between human immunodeficiency virus type 1 coinfection, anemia, and levels and function of antibodies to variant surface antigens in pregnancy-associated malaria. Clin Vaccine Immunol 2009;16:312-319.
316. Mount AM, et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 2004;363:1860-1867.
317. Keen J, et al. HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. PLoS Med 2007;4:e181.
318. Ataide R, et al. Using an improved phagocytosis assay to evaluate the effect of HIV on specific antibodies to pregnancy-associated malaria. PLoS ONE 2010;5:e10807.
319. Leeansyah E, Wines BD, Crowe SM, Jaworowski A. The mechanism underlying defective Fcgamma receptor-mediated phagocytosis by HIV-1-infected human monocyte-derived macrophages. J Immunol 2007;178:1096-1104.
320. Kedzierska K, Ellery P, Mak J, Lewin SR, Crowe SM, Jaworowski A. HIV-1 down-modulates gamma signaling chain of Fc gamma R in human macrophages: a possible mechanism for inhibition of phagocytosis. J Immunol 2002;168:2895-2903.
321. Ludlow LE, et al. HIV-1 inhibits phagocytosis and inflammatory cytokine responses of human monocyte-derived macrophages to P. falciparum infected erythrocytes. PLoS ONE 2012;7:e32102.
322. Reuben JM, et al. Induction of inflammatory cytokines in placental monocytes of gravidae infected with the human immunodeficiency virus type 1. J Interferon Cytokine Res 1996;16:963-971.
323. Davenport GC, Hittner JB, Were T, Ong'echa JM, Perkins DJ. Relationship between inflammatory mediator patterns and anemia in HIV-1 positive and exposed children with Plasmodium falciparum malaria. Am J Hematol 2012;87:652-658.
324. Hoffman IF, et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999;13:487-494.
325. Kublin JG, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005;365:233-240.
326. Kapiga SH, Bang H, Spiegelman D, et al. Correlates of plasma HIV-1 RNA viral load among HIV-1-seropositive women in Dar es Salaam. Tanzania. J Acquir Immune Defic Syndr 2002;30:316-323.
327. Mwapasa V, et al. The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS 2004;18:1051-1059.
328. Inion I, Mwanyumba F, Gaillard P, et al. Placental malaria and perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 2003;188:1675-1678.
329. Van Geertruyden JP, et al. CD4 T-cell count and HIV-1 infection in adults with uncomplicated malaria. J Acquir Immune Defic Syndr 2006;43:363-367.
330. Quigley MA, et al. The effect of malaria on mortality in a cohort of HIV-infected Ugandan adults. Trop Med Int Health 2005;10:894-900.
331. Mermin J, Lule JR, Ekwaru JP. Association between malaria and CD4 cell count decline among persons with HIV. J Acquir Immune Defic Syndr 2006;41:129-130.
332. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006;314:1603-1606.
333. Lawn SD, et al. Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans. AIDS 1999;13:2231-2237.
334. Xiao L, Owen SM, Rudolph DL, Lal RB, Lal AA. Plasmodium falciparum antigen-induced human immunodeficiency virus type 1 replication is mediated through induction of tumor necrosis factor-alpha. J Infect Dis 1998;177:437-445.
335. Finney CA, et al. HIV infection deregulates innate immunity to malaria despite combination antiretroviral therapy. AIDS 2013;27:325-335.
336. Tyagi RK, Garg NK, Sahu T. Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force. J Control Release 2012;162:242-254.
337. Agnandji ST, et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 2012;367:2284-2295.
338. Agnandji ST, et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011;365:1863-1875.
339. Hommel M, et al. Evaluation of the antigenic diversity of placenta-binding Plasmodium falciparum variants and the antibody repertoire among pregnant women. Infect Immun 2010;78:1963-1978.
340. Beeson JG, et al. Antigenic differences and conservation among placental Plasmodium falciparum-infected erythrocytes and acquisition of variant-specific and cross-reactive antibodies. J Infect Dis 2006;193:721-730.
341. Kane EG, Taylor-Robinson AW. Prospects and pitfalls of pregnancy-associated malaria vaccination based on the natural immune response to Plasmodium falciparum VAR2CSA-expressing parasites. Malar Res Treat 2011;2011:764845.
342. Feng G, et al. Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes are associated with protection from treatment failure and the development of anemia in pregnancy. J Infect Dis 2009;200:299-306.
343. Aderem A, et al. A systems biology approach to infectious disease research: innovating the pathogen-host research paradigm. MBio 2011;2:e00325-10.
344. Tran TM, Samal B, Kirkness E, Crompton PD. Systems immunology of human malaria. Trends Parasitol 2012;28:248-257.
345. Nolan GP. Flow cytometry in the post fluorescence era. Best Pract Res Clin Haematol 2011;24:505-508.
346. Qiu P, et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol 2011;29:886-891.